Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Rekha Kumar, MD, endocrinologist, obesity medicine specialist, and senior medical adviser at Found, explains, Tirzepatide can slow down digestive motility, meaning food moves through the intestines more slowly
The SURPASS-CVOT trial is specifically evaluating tirzepatide cardiovascular outcomes
Patients should be counseled that experiencing some gastrointestinal discomfort is normal and does not indicate treatment failure or intolerance, provided symptoms remain manageable
They are consistent with the known side effect profile of GLP-1 receptor agonists already approved in the UK (see, for example, the Wegovy Summary of Product Characteristics, available via the electronic Medicines Compendium)
US$ 23.43
US$ 23.27
US$ 20.86
US$ 22.93
US$ 20.29
